Litigation Daily: “Killer Crosses: How Wilkinson Walsh Partners Shredded Witnesses in $600M Save for Bayer”

After the Wilkinson Walsh team, led by Sean Eskovitz, Alex Walsh, James Rosenthal, and Kieran Gostin, won a decisive victory for Bayer in a $600 million certified consumer class action lawsuit brought on behalf of One A Day multivitamin consumers, Litigation Daily‘s Jenna Greene wrote about how Eskovitz and Walsh were “so good” at the cross-examinations that “the Wilkinson Walsh team called no defense witnesses. They annihilated the case on crosses alone”: If cross-examination is an art form, then Wilkinson Walsh name partners Alexandra Walsh and Sean Eskovitz (pictured above) are masters. The duo led a trial team defending Bayer AG, which faced a $600 million certified consumer class action over its One A Day multivitamin. The plaintiffs alleged Bayer made false and misleading claims that One A Day supported heart health, immunity and physical energy. How good were the cross-examinations? So good that that the Wilkinson Walsh team called no defense witnesses. They annihilated the case on …

Wilkinson Walsh Secures Trial Win for Bayer in $600 Million One A Day Class Action

WASHINGTON, D.C. — The Wilkinson Walsh team, led by Sean Eskovitz, Alex Walsh, James Rosenthal, and Kieran Gostin, won a decisive victory for Bayer in a $600 million certified consumer class action lawsuit brought on behalf of One A Day multivitamin consumers.  Without calling any witnesses in the defense case, the team relied on devastating cross-examinations of plaintiffs’ expert and fact witnesses to convince the jury to reject plaintiffs’ claims that Bayer had misrepresented the health benefits of One A Day multivitamins.  The jury deliberated for just an hour before returning a complete defense verdict.  The class action suit, filed on behalf of purchasers of One A Day multivitamins in California, New York, and Florida, challenged as false and misleading Bayer’s claims that One A Day multivitamins support heart health, immunity, and physical energy. Plaintiffs originally sought over $4 billion in damages, which Wilkinson Walsh successfully reduced to $600 million …

Wilkinson Walsh Celebrates Banner Year of High Stakes Trial Wins By Next Generation Of Trial Lawyers

WASHINGTON – Wilkinson Walsh is racing into its fourth year after notching a series of high-profile victories, led by a large and diverse group of partners. In 2018, all of Wilkinson Walsh’s partners participated in trials and case-dispositive hearings, and several other attorneys achieved significant on-their-feet experience, including through pro bono cases. The firm earned repeated recognition for the depth and successes of its bench and added a new crop of talented litigators to its roster. Wilkinson Walsh won three trials in 2018, each of which was first-chaired by a different partner: On April 27, 2018, Wilkinson Walsh, led by Brian Stekloff, Jeremy Barber, and Lori McGill, won a unanimous defense verdict for Bayer and Johnson & Johnson subsidiary Janssen Pharmaceuticals in Russell v. Janssen Pharmaceuticals, Inc., the second state-court Xarelto bellwether trial in the Pennsylvania Court of Common Pleas. On May 21, 2018, Wilkinson Walsh, led by Kosta Stojilkovic …

Appeals Court Upholds Major Antitrust Win for Wilkinson Walsh Client Georgia Pacific

WASHINGTON,D.C. — The U.S. Court of Appeals for the Seventh Circuit unanimously upheld a major trial court win for Wilkinson Walsh client Georgia Pacific, affirming the dismissal of a high stakes antitrust class action lawsuit involving over $10 billion in claimed damages. Georgia Pacific hired Wilkinson Walsh to handle all aspects of summary judgment briefing and trial after the trial court certified Plaintiffs’ proposed class. The Wilkinson Walsh team, led by Beth Wilkinson, Alexandra Walsh, Brant Bishop, and Rakesh Kilaru, developed an evidentiary record focused on the absence of any evidence against Georgia Pacific, and filed independent briefs challenging Plaintiffs’ expert witnesses and seeking summary judgment. In June 2017, the court issued a Daubert opinion that imposed key limits on the testimony Plaintiffs’ witnesses could offer at trial, adopting several of Wilkinson Walsh’s arguments. On August 3, 2017, Wilkinson Walsh won summary judgment for Georgia Pacific. The court’s decision came …

Benchmark Names Beth Wilkinson an “Elite” Top 100 Trial Lawyer

Washington, D.C. — Wilkinson Walsh Founding Partner Beth Wilkinson has been named a Top 100 Trial Lawyer by Benchmark Litigation 2018. The award recognizes “elite trial strategists” for their successes in the courtroom. “At this point, it goes without saying that Beth’s recognitions are well-deserved. She is continuously recognized as a top trial lawyer precisely because of the high-profile victories she delivers for her clients and her role as a trailblazer in and outside of the courtroom,” said Wilkinson Walsh Founding Partner Alexandra Walsh. “She is a role model for our firm’s younger associates, a force to be reckoned with when in front of a jury, and a paragon of success in the legal community at large.” Since founding Wilkinson Walsh less than three years ago, Beth has notched a string of standout trial victories, been honored and recognized for her and Wilkinson Walsh’s various successes, and built the firm …

WWE PARTNER ALEXANDRA WALSH NAMED LITIGATOR OF THE WEEK

Award recognizes her role leading the Wilkinson, Walsh + Eskovitz team to another victory WASHINGTON – Litigation Daily selected Wilkinson Walsh Founding Partner Alexandra Walsh as its Litigator of the Week for her role persuading a Philadelphia jury to find for the defense in a bellwether trial over the adequacy of the warning labels for the blood thinner Xarelto. Walsh, along with partners Tamarra Matthews Johnson and Rakesh Kilaru, won the third state-court bellwether trial over the blood- thinner Xarelto in the Pennsylvania Court of Common Pleas in August. The victory was the third win for Bayer in state court, and the sixth win overall, in the Xarelto litigation. Read her Q&A with Lit Daily Editor Jenna Greene here. Walsh and Johnson served as lead trial counsel for Bayer, and Kilaru helped direct the legal strategy. A 12-member jury in Philadelphia returned a defense verdict after less than three hours …

Wilkinson Walsh Secures Another Trial Victory for Bayer in Xarelto Trial

Alexandra Walsh, co-founding partner of Wilkinson, Walsh + Eskovitz, Tamarra Matthews Johnson, and Rakesh Kilaru led the defense team to another victory. WASHINGTON – The Wilkinson Walsh trial team, led by Founding Partner Alexandra Walsh and partners Tamarra Matthews Johnson and Rakesh Kilaru, won the third state-court bellwether trial over the blood- thinner Xarelto in the Pennsylvania Court of Common Pleas. This is the third win for Bayer in state court, and the sixth win overall, in the Xarelto litigation. The Plaintiff, Kevin Cooney, alleged that Bayer and Johnson & Johnson subsidiary Janssen Pharmaceuticals were liable for claims that the Xarelto label did not adequately warn or instruct doctors on the risks of bleeding associated with the anticoagulant medicine Xarelto. Walsh and Johnson served as lead trial counsel for Bayer, and Kilaru helped direct the legal strategy. A 12-member jury in Philadelphia returned a defense verdict after less than three …

Three Wilkinson Walsh Partners Named “Top Women in Litigation” by Benchmark

WASHINGTON – Wilkinson Walsh Partners Beth Wilkinson, Alexandra Walsh, and Lori Alvino McGill were ranked among Benchmark Litigation’s “Top 250 Women in Litigation,” all of whom “share the distinction of being recognized as top players in their respective fields.” Founding Partner Beth Wilkinson was also named among the “Top 10 Female Litigators” in the country. Benchmark’s “Top 250 Women in Litigation” rankings recognize women who “have earned their place amongst the leading female litigators by participating in some of the most impactful litigation matters in recent history as well as by earning the hard-won respect of their peers and clients.” “Benchmark’s recognition of Beth, Alex, and Lori as leaders in our field is a great honor, reflecting the firm’s strong female leadership in a male-dominated industry,” said Wilkinson Walsh Managing Partner Brant Bishop. “We’re proud to call Beth, Alex, and Lori our partners, and feel strongly that our firm’s diversity …

Wilkinson Walsh Selected As Industry-Leading “Best Law Firm For Female Attorneys”

WASHINGTON – Wilkinson Walsh was named the fifth best law firm for female attorneys among all firms with 20 to 149 lawyers in Law360’s 2018 Glass Ceiling report. Though women represent just over one-third of all attorneys in private practice, Law360 recognized Wilkinson Walsh for its strong female leadership, including two female name partners, and for achieving gender parity among the firm’s attorneys. “Having a diverse workforce is not just the right thing to do, but it also enhances the strength and quality of our firm, including our ability to deliver victories in the courtroom,” said Wilkinson Walsh Founding Partner Beth Wilkinson. “Wilkinson Walsh’s diversity may make our firm the exception, not the rule — but it certainly is the model of the future.” “When we started this firm over two years ago, we agreed that diversity in all forms was an important and essential virtue of the firm,” said …

Wilkinson Walsh Wins Victory for Bayer in First State-Court Xarelto Trial

WASHINGTON – On January 9, 2018, Wilkinson Walsh, led by Founding Partners Beth Wilkinson and Alexandra Walsh, won the first state-court bellwether trial over the blood-thinner Xarelto when the trial court entered judgment for Bayer and Janssen notwithstanding a jury verdict in favor of the plaintiff.  Wilkinson and Wilkinson Walsh had previously secured two full defense verdicts for Bayer in similar cases in the federal multi-district litigation in Louisiana. In December 2017, a jury in the Philadelphia Court of Common Pleas awarded nearly $28 million to plaintiff Lynn Hartman in a lawsuit that alleged that Bayer and Johnson & Johnson subsidiary Janssen Pharmaceuticals were liable for claims that the Xarelto label did not adequately instruct doctors on the risks of bleeding associated with the anticoagulant Xarelto.  Bayer and Janssen then filed motions for judgment notwithstanding the verdict and a new trial.  The motions raised two key points (among many others).  …